(Q43263556)

17 November 2017

title

Pre-therapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-Hodgkin lymphoma (English)

1 reference

17 November 2017

Nacim Betrouni

4

0 references

author name string

Thomas Cazaentre

1

1 reference

17 November 2017

Franck Morschhauser

2

1 reference

17 November 2017

Maximilien Vermandel

3

1 reference

17 November 2017

Thierry Prangère

5

1 reference

17 November 2017

Marc Steinling

6

1 reference

17 November 2017

Damien Huglo

7

1 reference

17 November 2017

publication date

30 September 2009

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

17 November 2017

published in

1 reference

17 November 2017

volume

37

1 reference

17 November 2017

issue

3

1 reference

17 November 2017

page(s)

494-504

1 reference

https://scigraph.springernature.com/pub.10.1007/s00259-009-1275-x

17 November 2017

exact match

0 references

cites work

Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00259-009-1275-X

Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

12 December 2020

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

12 December 2020

18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy

1 reference

12 December 2020

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

12 December 2020

PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.

1 reference

12 December 2020

Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.

1 reference

12 December 2020

Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?

1 reference

12 December 2020

The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma

1 reference

12 December 2020

Revised response criteria for malignant lymphoma

1 reference

12 December 2020

Anatomy of SUV. Standardized uptake value

1 reference

12 December 2020

Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity

1 reference

12 December 2020

Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation

1 reference

12 December 2020

Follicular lymphoma international prognostic index.

1 reference

12 December 2020

B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience

1 reference

12 December 2020

Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET

1 reference

12 December 2020

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

1 reference

12 December 2020

Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab

1 reference

12 December 2020

FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

1 reference

12 December 2020

90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.

1 reference

12 December 2020

Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography

1 reference

12 December 2020

Factors associated with toxicity and response to yttrium 90-labeled ibritumomab tiuxetan in patients with indolent non-Hodgkin's lymphoma.

1 reference

12 December 2020

Radioimmunotherapy of non-Hodgkin's lymphomas

1 reference

12 December 2020

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

1 reference

12 December 2020

Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis

1 reference

12 December 2020

Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma

1 reference

12 December 2020

Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma

1 reference

12 December 2020

Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.

1 reference

12 December 2020

Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study

1 reference

12 December 2020

Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues

1 reference

12 December 2020

Early therapy monitoring with FDG-PET in aggressive non-Hodgkin?s lymphoma and Hodgkin?s lymphoma

1 reference

12 December 2020

Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation

1 reference

12 December 2020

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

1 reference

12 December 2020

Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET

1 reference

12 December 2020

90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging

1 reference

12 December 2020

Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET.

1 reference

12 December 2020

Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?

1 reference

12 December 2020

Report of the Committee on Hodgkin's Disease Staging Classification

1 reference

12 December 2020

The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis

1 reference

12 December 2020

Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma

1 reference

12 December 2020

10.1007/S00259-009-1275-X

Identifiers

DOI

1 reference

release_lmhrmk74enc65mjxe7f5sufimi

17 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lmhrmk74enc65mjxe7f5sufimi

24 November 2022

mapped directly with Wikidata item

1 reference